KR102813615B1 - 폴리뉴클레오티드-연결된 바이오컨쥬게이트 및 제조 및 이용 방법 - Google Patents

폴리뉴클레오티드-연결된 바이오컨쥬게이트 및 제조 및 이용 방법 Download PDF

Info

Publication number
KR102813615B1
KR102813615B1 KR1020227015133A KR20227015133A KR102813615B1 KR 102813615 B1 KR102813615 B1 KR 102813615B1 KR 1020227015133 A KR1020227015133 A KR 1020227015133A KR 20227015133 A KR20227015133 A KR 20227015133A KR 102813615 B1 KR102813615 B1 KR 102813615B1
Authority
KR
South Korea
Prior art keywords
nucleic acid
polynucleotide
acid linker
modified
substrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020227015133A
Other languages
English (en)
Korean (ko)
Other versions
KR20220088437A (ko
Inventor
크레이그 라보다
마이클 스타드니스키
크리스토퍼 드와이어
Original Assignee
피토넥스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 피토넥스, 인코포레이티드 filed Critical 피토넥스, 인코포레이티드
Publication of KR20220088437A publication Critical patent/KR20220088437A/ko
Application granted granted Critical
Publication of KR102813615B1 publication Critical patent/KR102813615B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/544—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic
    • G01N33/548—Carbohydrates, e.g. dextran
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2563/00—Nucleic acid detection characterized by the use of physical, structural and functional properties
    • C12Q2563/107—Nucleic acid detection characterized by the use of physical, structural and functional properties fluorescence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2563/00—Nucleic acid detection characterized by the use of physical, structural and functional properties
    • C12Q2563/131—Nucleic acid detection characterized by the use of physical, structural and functional properties the label being a member of a cognate binding pair, i.e. extends to antibodies, haptens, avidin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2563/00—Nucleic acid detection characterized by the use of physical, structural and functional properties
    • C12Q2563/149—Particles, e.g. beads
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2563/00—Nucleic acid detection characterized by the use of physical, structural and functional properties
    • C12Q2563/179—Nucleic acid detection characterized by the use of physical, structural and functional properties the label being a nucleic acid
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2458/00—Labels used in chemical analysis of biological material
    • G01N2458/10—Oligonucleotides as tagging agents for labelling antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
KR1020227015133A 2019-10-25 2020-10-24 폴리뉴클레오티드-연결된 바이오컨쥬게이트 및 제조 및 이용 방법 Active KR102813615B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962926037P 2019-10-25 2019-10-25
US62/926,037 2019-10-25
PCT/US2020/057247 WO2021081466A1 (en) 2019-10-25 2020-10-24 Polynucleotide-linked bioconjugates and methods of making and using

Publications (2)

Publication Number Publication Date
KR20220088437A KR20220088437A (ko) 2022-06-27
KR102813615B1 true KR102813615B1 (ko) 2025-05-29

Family

ID=75620294

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227015133A Active KR102813615B1 (ko) 2019-10-25 2020-10-24 폴리뉴클레오티드-연결된 바이오컨쥬게이트 및 제조 및 이용 방법

Country Status (7)

Country Link
US (3) US12558433B2 (OSRAM)
EP (1) EP4048313A4 (OSRAM)
JP (1) JP2022553737A (OSRAM)
KR (1) KR102813615B1 (OSRAM)
CN (1) CN114555125A (OSRAM)
AU (1) AU2020370590B2 (OSRAM)
WO (1) WO2021081466A1 (OSRAM)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116207451B (zh) 2021-12-01 2026-02-27 株式会社Lg新能源 圆筒形电池及应用于其的集电体、包括其的电池组及汽车

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013177046A1 (en) * 2012-05-21 2013-11-28 Solulink, Inc. Methods and/or use of oligonucleotide conjugates for suppressing background due to cross-hybridization
US8946389B2 (en) 2011-04-25 2015-02-03 University Of Washington Compositions and methods for multiplex biomarker profiling
US20150344937A1 (en) 2012-06-15 2015-12-03 The University Of Chicago Oligonucleotide-mediated quantitative multiplexed immunoassays
US9612236B2 (en) 2010-06-17 2017-04-04 Koninklijke Philips N.V. Multi epitope assay
WO2018022809A1 (en) 2016-07-27 2018-02-01 The Board Of Trustees Of The Leland Stanford Junior University Highly-multiplexed fluorescent imaging
WO2018234473A1 (en) 2017-06-21 2018-12-27 Dynamic Biosensors Gmbh Method for detecting and/or characterizing the interaction between proteins and small molecules

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1816192B1 (en) * 2004-10-15 2012-12-12 National Institute of Advanced Industrial Science and Technology LINKER FOR CONSTRUCTING mRNA-PUROMYCIN-PROTEIN CONJUGATE
US7494776B2 (en) * 2005-07-07 2009-02-24 Beckman Coulter, Inc. Labeled complementary oligonucleotides to detect oligonucleotide-linked ligands
JP2007275006A (ja) 2006-04-10 2007-10-25 Hitachi High-Technologies Corp 核酸検出用プローブ作製法
US8309306B2 (en) 2008-11-12 2012-11-13 Nodality, Inc. Detection composition
US8946289B2 (en) * 2008-11-19 2015-02-03 Duke University Manassatin compounds and methods of making and using the same
EP2401607B1 (en) 2009-02-25 2015-11-25 Illumina, Inc. Separation of pyrophosphate release and pyrophosphate detection
WO2011120046A2 (en) 2010-03-26 2011-09-29 Swift Biosciences, Inc. Methods and compositions for isolating polynucleotides
JP5759678B2 (ja) * 2010-04-14 2015-08-05 国立大学法人埼玉大学 核酸リンカー
ES2747842T3 (es) * 2014-12-15 2020-03-11 Dicerna Pharmaceuticals Inc Acidos nucleicos de doble hebra modificados por ligando
CN108291257B (zh) * 2015-09-24 2023-12-29 阿布维特罗有限责任公司 亲和-寡核苷酸缀合物及其用途
JP7270254B2 (ja) * 2017-06-16 2023-05-10 デューク ユニバーシティ 改善された標識検出、演算、検体感知、および調整可能な乱数生成のための共鳴体ネットワーク

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9612236B2 (en) 2010-06-17 2017-04-04 Koninklijke Philips N.V. Multi epitope assay
US8946389B2 (en) 2011-04-25 2015-02-03 University Of Washington Compositions and methods for multiplex biomarker profiling
WO2013177046A1 (en) * 2012-05-21 2013-11-28 Solulink, Inc. Methods and/or use of oligonucleotide conjugates for suppressing background due to cross-hybridization
US20150344937A1 (en) 2012-06-15 2015-12-03 The University Of Chicago Oligonucleotide-mediated quantitative multiplexed immunoassays
WO2018022809A1 (en) 2016-07-27 2018-02-01 The Board Of Trustees Of The Leland Stanford Junior University Highly-multiplexed fluorescent imaging
WO2018234473A1 (en) 2017-06-21 2018-12-27 Dynamic Biosensors Gmbh Method for detecting and/or characterizing the interaction between proteins and small molecules

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Amy C Flor et al, Chembiochem (2013.12.27.), vol 15, no 2, pp 267-275.
Park Jun Young et al, Biomaterials (2016.5.24.), vol 100, pp 143-151.

Also Published As

Publication number Publication date
CN114555125A (zh) 2022-05-27
WO2021081466A1 (en) 2021-04-29
AU2020370590B2 (en) 2025-01-02
US20220168441A1 (en) 2022-06-02
EP4048313A4 (en) 2023-05-31
US20240156981A1 (en) 2024-05-16
JP2022553737A (ja) 2022-12-26
KR20220088437A (ko) 2022-06-27
US12558433B2 (en) 2026-02-24
AU2020370590A1 (en) 2022-04-14
EP4048313A1 (en) 2022-08-31
US20220218841A1 (en) 2022-07-14

Similar Documents

Publication Publication Date Title
JP4511363B2 (ja) 相互作用する分子を検出するためのｆｒｅｔプローブおよび方法
Chamma et al. Mapping the dynamics and nanoscale organization of synaptic adhesion proteins using monomeric streptavidin
JP5860922B2 (ja) ビーズまたは他の捕捉物を用いた分子または粒子の超高感度検出
US20150004598A1 (en) Compositions and methods for multiplex biomarker profiling
CN108350483A (zh) 在用户定义的切片组织区域中同时定量多种蛋白质
Platzer et al. Unscrambling fluorophore blinking for comprehensive cluster detection via photoactivated localization microscopy
Schirripa Spagnolo et al. Choosing the probe for single-molecule fluorescence microscopy
KR20200024736A (ko) 타겟 물질 검출을 위한 방법 및 키트
US20250092441A1 (en) Sequential staining for multiplex analyses of tissues and cells
US20100216652A1 (en) Low Level Fluorescence Detection at the Light Microscopic Level
Mahmoud et al. Advanced procedures for labeling of antibodies with quantum dots
JP4594733B2 (ja) 腫瘍特異的融合蛋白質の検出のための方法およびプローブ
US20240156981A1 (en) Polynucleotide-linked bioconjugates and methods of making and using
KR101270094B1 (ko) Ｃｍｏｓ 기반 세포 이미징 분석 시스템
Lee et al. Immuno-nanoparticles for multiplex protein imaging in cells and tissues
WO2017165745A1 (en) Selectively and fully cleavable fluorescent probes for sequential, itrative immunostaining
US20260009716A1 (en) Quantitative measurement of molecules using single molecule fluorescence microscopy
JP2018537071A (ja) 固定化された核酸を使用して分子相互作用を検出するための方法
US20240226344A1 (en) Nucleic acid origami platforms and their uses
US20240002911A1 (en) Methods Of Signal Amplification
CN116457471A (zh) 信号放大方法
CN116829728A (zh) 用于多重和多模式单细胞分析的方法和组合物
JP2010104297A (ja) ｓｉＲＮＡによるＲＮＡ切断反応の検出方法
Kim et al. Multiplexed Detection Using Quantum Dots

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20220504

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20221021

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240619

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20250423

PG1601 Publication of registration